Why bluebird bio Inc Continued Its March Higher Again Today
Shares of bluebird bio (NASDAQ: BLUE) continued their seemingly unstoppable march higher this week, jumping another 10.8% today as of 2:58 p.m. EDT after two analysts increased their price targets on the biotech. All told, Bluebird is up a whopping 27% for the week -- and it's only Thursday.
This occurred after Gilead Sciences (NASDAQ: GILD) announced the acquisition of fellow CAR-T biotech Kite Pharma (NASDAQ: KITE), driving acquisition speculation on Monday. The Food and Drug Administration (FDA) also approved Novartis' (NYSE: NVS) Kymriah yesterday, suggesting Bluebird might have an easy time getting its own CAR-T treatment, bb2121, approved.
Image source: Getty Images.
Source: Fool.com
Gilead Sciences Inc Stock
€70.64
-1.120%
We see a rather positive sentiment for Gilead Sciences Inc with 12 Buy predictions and 1 Sell predictions.
With a target price of 84 € there is a slightly positive potential of 18.91% for Gilead Sciences Inc compared to the current price of 70.64 €.
